Bumble Inc. (NASDAQ: BMBL): HSBC Securities initiated coverage with a Buy rating and a $20.30 target price. The consensus target is $23.57, and shares closed on Tuesday at $14.79.
Carlisle Companies Inc. (NYSE: CSL): As Jefferies downgraded the stock to Hold from Buy, its $325 price target shrank to $290. The consensus target is $320, and shares closed on Tuesday at $253.45.
Comerica Inc. (NYSE: CMA): Odeon’s downgrade was from Buy to Hold with a $46 target price. The consensus target is $57.48. The stock closed on Tuesday at $39.99.
Dell Technologies Inc. (NYSE: DELL): Citing an AI-driven rebound in PC sales and growth in server sales, Zacks selected this as its Bull of the Day stock. Shares last closed at $68.93, which is up more than 34% in the past 90 days.
Domino’s Pizza Inc. (NYSE: DPZ): Oppenheimer reiterated an Outperform rating with a $450 target price. That compares with the $417.85 consensus target and Tuesday’s closing print of $379.22.
Edwards Lifesciences Corp. (NYSE: EW): Oppenheimer upgraded the stock to Outperform from Perform, but its $90 price target is less than the consensus target of $97.05. The shares closed at $70.37 on Tuesday.
Etsy Inc. (NASDAQ: ETSY): Evercore ISI reiterated an Outperform rating but reduced its target price to $85 from $105. The consensus target is $106.33. Tuesday’s close at $61.87 was down over 4% on the day.
Fisker Inc. (NYSE: FSR): BofA Securities resumed coverage with a Buy rating and has an $8 price target. The consensus target is $8.95. The stock closed almost 10% higher on Tuesday at $5.82 after the upgrade.
Flowserve Corp. (NYSE: FLS): Jefferies upgraded the stock to Buy from Hold and lifted its price target to $50 from $40. The consensus target is $43,60. The shares closed Tuesday’s session at $38.90.
Immunovant Inc. (NASDAQ: IMVT): Raymond James upgraded the shares to Outperform from Market Perform. Its $40 target price is well above the consensus target of $29.92. The stock closed Tuesday at $39.96, which was up 97% for the day after the company announced its experimental drug lowered an antibody tied to autoimmune diseases.
Luminar Technologies Inc. (NASDAQ: LAZR): BofA Securities resumed coverage with a Neutral rating and a $5 price target. The consensus target is $11.14. The stock closed over 6% lower on Tuesday at $4.01.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
